Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HISTORIA: HIPEC + PD-1 + SOX for Gastric Cancer with Peritoneal Metastasis
NCT06427252Phase 2Active, not recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in gastric cancer (GC), esophagogastric junction cancer, sponsored by Jiangsu Provincial People's Hospital. Started May 2024; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on NCT06427252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06427252.